Navigation Links
The potential of psilocybin to alleviate psychological distress in cancer patients is revealed
Date:1/31/2013

Improvements in the diagnosis and treatment of cancers in recent years have led to a marked increase in patients' physical survival rates. While doctors can treat the physical disease, what is not well understood is how best to address the psychological needs of patients with cancer.

In addition to the physical pain associated with cancer, many patients also experience psychologically harmful symptoms of anxiety, depression, anger, and denial. Social isolation, in addition to hopelessness, helplessness and loss of independence, has also been associated with significant psychological suffering in patients coping with advanced-stage cancer.

A recently published book chapter "Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer," reviews the potential of a novel psychoactive drug, psilocybin, in alleviating the psychological and spiritual distress that often accompanies a life-threatening cancer diagnosis.

The chapter, published in Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes, and Their Management, was co-written by Anthony P. Bossis, PhD, Clinical Assistant Professor of Psychiatry and Oral and Maxillofacial Pathology, Radiology, and Medicine at the New York University College of Dentistry (NYUCD) and Langone Medical Center.

The hallucinogen treatment model with psilocybin has been shown to induce a mystical or spiritual experience and is a unique therapeutic approach to reduce the anxiety of terminal cancer patients.

"Mystical or peak consciousness states in cancer patients have been associated with a number of benefits including improved psychological, spiritual, and existential well-being," said Dr. Bossis.

Psilocybin (a serotonergic psychoactive agent) is a naturally occurring active component of many species of mushrooms, and is rapidly metabolized to psilocin, a highly potent activator of serotonin receptors. In addition to receiving the psilocybin compound, patients enrolled in the study also receive psychological preparation prior to the psilocybin dosing followed by a brief series of integrative psychotherapeutic sessions.

The chapter includes a clinical case vignette of a patient in the ongoing Psilocybin Cancer Anxiety Study at the Bluestone Center for Clinical Research. Participants undergo two drug administration sessions in which psilocybin is administered on one occasion and a placebo on the other.

"The primary objective of this phase I, double-blind, controlled pilot study is to assess the efficacy of psilocybin administration on psychosocial distress, with the specific primary outcome variable being anxiety associated with advanced and/or recurrent cancer," said Bossis. "Secondary outcome measures will look at the effect of psilocybin on symptoms of pain perception, depression, existential/psychospiritual distress, attitudes toward illness, quality of life, and spiritual/mystical states of consciousness," said Bossis.

The clinical vignette describes a patient who, over the course of three years, experienced extreme fatigue, pain, overall body aches, discomfort and psychological distress due to cancer and intensive biweekly chemotherapy. The patient became increasingly anxious and depressed and was enrolled in two study sessions; in one he received psilocybin and the other placebo. Despite continuing the arduous chemotherapy schedule, suffering from illness, and undergoing additional surgical procedures, the patient continued to report a marked improvement in attitude, coping, and mood 18 weeks after his session and stated, "my quality of life is dramatically improved," the patient said.


'/>"/>

Contact: Christopher James
christopher.james@nyu.edu
212-998-6876
New York University
Source:Eurekalert

Related biology news :

1. BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection
2. Underwater CO2 shows potential as barrier to Asian carp
3. Circadian rhythms can be modified for potential treatment of disorders
4. Potential harvest of most fish stocks largely unrelated to abundance
5. Scripps Florida scientists uncover potential drug target to block cell death in Parkinsons disease
6. Tree seeds offer potential for sustainable biofuels
7. BPA linked to potential adverse effects on heart and kidneys
8. Transplanted genetically-modified adipose cells offer potential therapy for liver diseases
9. Serendipity points to new potential target and therapy for melanoma
10. Potential gene therapy approach to sickle cell disease highlighted at ASH
11. New coronavirus has many potential hosts, could pass from animals to humans repeatedly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... ... Dr. Asher Kimchi, Founder and Chairman of the International Academy of ... 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. In addition to ... Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. Elefteriades and Dr. ...
(Date:7/20/2017)... , ... July 20, 2017 , ... Corporate Directors Forum ... its 27th annual Director of the Year Awards. , The awards will be presented ... This annual event celebrates directors who have made significantly positive contributions in the ...
(Date:7/18/2017)... ... 18, 2017 , ... G-CON today announced that it has ... its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. ... the protection of G-CON’s R&D investments and validate the G-CON platform as a ...
(Date:7/17/2017)... ... ... The Academy of Model Aeronautics (AMA) will host Aviation Adventure Day on ... from 9 a.m. to 2 p.m. at the International Aeromodeling Center in Muncie, Indiana. ... Day will be packed with entertaining activities for the entire family. Attendees will learn ...
Breaking Biology Technology: